961 related articles for article (PubMed ID: 21348383)
1. Impact of combination therapy with peritoneal dialysis and hemodialysis on peritoneal function.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2010; 26():67-70. PubMed ID: 21348383
[TBL] [Abstract][Full Text] [Related]
2. Peritoneal dialysis patients with high effluent fibrin degradation products.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2009; 25():41-4. PubMed ID: 19886315
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of dialysis dose during combination therapy with peritoneal dialysis and hemodialysis.
Kawanishi H; Moriishi M; Tsuchiya S
Adv Perit Dial; 2007; 23():135-9. PubMed ID: 17886620
[TBL] [Abstract][Full Text] [Related]
5. Combined peritoneal dialysis and hemodialysis therapy improves quality of life in end-stage renal disease patients.
Hashimoto Y; Matsubara T
Adv Perit Dial; 2000; 16():108-12. PubMed ID: 11045273
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of the dialysis adequacy and transport test in peritoneal dialysis.
Seo JJ; Kim YL; Park SH; Kim CD; Kim JC; Jang MH; Choi HJ
Adv Perit Dial; 2005; 21():25-30. PubMed ID: 16686280
[TBL] [Abstract][Full Text] [Related]
7. High membrane transport status on peritoneal dialysis is not associated with reduced survival following transfer to haemodialysis.
Wiggins KJ; McDonald SP; Brown FG; Rosman JB; Johnson DW
Nephrol Dial Transplant; 2007 Oct; 22(10):3005-12. PubMed ID: 17545674
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal transport status correlates with morbidity but not longitudinal change of nutritional status of continuous ambulatory peritoneal dialysis patients: a 2-year prospective study.
Szeto CC; Law MC; Wong TY; Leung CB; Li PK
Am J Kidney Dis; 2001 Feb; 37(2):329-36. PubMed ID: 11157374
[TBL] [Abstract][Full Text] [Related]
9. Fibrin degradation products are a useful marker for the risk of encapsulating peritoneal sclerosis.
Moriishi M; Kawanishi H
Adv Perit Dial; 2008; 24():56-9. PubMed ID: 18986002
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of body size indices, residual renal function, and peritoneal transport characteristics in continuous ambulatory peritoneal dialysis.
Twardowski ZJ; Moore HL; Prowant BF; Satalowich R
Adv Perit Dial; 2009; 25():155-64. PubMed ID: 19886338
[TBL] [Abstract][Full Text] [Related]
11. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
12. Five years' experience of combination therapy: peritoneal dialysis with hemodialysis.
Kawanishi H; Moriishi M; Tsuchiya S
Adv Perit Dial; 2002; 18():62-7. PubMed ID: 12402589
[TBL] [Abstract][Full Text] [Related]
13. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters.
Rodrigues AS; Martins M; Korevaar JC; Silva S; Oliveira JC; Cabrita A; Castro e Melo J; Krediet RT
Am J Nephrol; 2007; 27(1):84-91. PubMed ID: 17284895
[TBL] [Abstract][Full Text] [Related]
15. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2006; 22():24-8. PubMed ID: 16983933
[TBL] [Abstract][Full Text] [Related]
16. Hemodialysis together with peritoneal dialysis is one of the simplest ways to maintain adequacy in continuous ambulatory peritoneal dialysis.
Kawanishi H; Moriishi M; Katsutani S; Sakikubo E; Tsuchiya S
Adv Perit Dial; 1999; 15():127-31. PubMed ID: 10682087
[TBL] [Abstract][Full Text] [Related]
17. What is good about PD + HD combined therapy.
Yamashita AC; Tomisawa N
Hemodial Int; 2011 Oct; 15 Suppl 1():S15-21. PubMed ID: 22093595
[TBL] [Abstract][Full Text] [Related]
18. Differences in peritoneal equilibration test results in patients aged above or below 60 years.
Grzegorzewska AE; Leander M; Mariak I
Adv Perit Dial; 2002; 18():33-9. PubMed ID: 12402583
[TBL] [Abstract][Full Text] [Related]
19. Outcome of hemodialysis patients who had failed peritoneal dialysis.
Szeto CC; Kwan BC; Chow KM; Pang WF; Kwong VW; Leung CB; Li PK
Nephron Clin Pract; 2010; 116(4):c300-6. PubMed ID: 20639677
[TBL] [Abstract][Full Text] [Related]
20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
